Compounding Pharmacies vs. Approved Drug Manufacturing: 503A and 503B Basics

Three different pathways

U.S. drug and compounding oversight is easier to follow if you keep three lanes separate:

### 1. FDA-approved drug manufacturing

Manufacturers obtain approval (for example, via NDA or BLA pathways) for specific finished products, with labeling, manufacturing controls, and post-market obligations tied to that approval. “FDA approved” refers to this lane — not to advisory votes about bulk substances.

### 2. Traditional compounding (503A)

State-licensed pharmacies compound pursuant to an individual prescription under Section 503A conditions. Bulk substance use is constrained by statute and FDA’s bulks-list framework. A 503A compounded preparation is not automatically an “FDA-approved drug.”

### 3. Outsourcing facilities (503B)

503B facilities register with FDA and operate under a different compounding regime than traditional 503A pharmacies. Quality and reporting expectations differ. Again, 503B compounding is not the same as NDA/BLA approval.

Why headlines blur the lanes

Advisory meetings about bulk substances sit mostly in the **503A listing** conversation. Coverage that says a vote “approves a drug” borrows language from Lane 1 while describing an event in Lane 2’s rulemaking pipeline. That shorthand spreads false certainty.

Research suppliers are a fourth context

Research-use suppliers are not compounding pharmacies and are not approved drug manufacturers. Their compliance posture depends on truthful RUO positioning and consistent communications — separate from whether FDA eventually lists a bulk substance for 503A compounding.

A simple sorting rule

When you read a compounding article, ask: is this about **approved products**, **503A pharmacy compounding**, **503B outsourcing**, or **research materials**? If the article never says, the conclusion is not ready to trust.

*For research use only. Not for human or animal consumption.*